Sign up for ourE-News

ROMIDEPSIN (Istodax®)

Romidepsin is a targeted therapy medicine used in the treatment of Peripheral T Cell Lymphoma (PTCL) and Cutaneous T Cell Lymphoma (CTCL). Romidepsin is isolatedfrom a bacterium called Chromobacterium violaceum and is thought to reduce the growth and division of lymphoma cells by inhibiting the process involved in the regulation in these lymphomas.

Romidepsin is given by intravenous infusion which means it goes directly into the vein through a needle in your arm or through a central line if you have one in place. Romidepsinis given every week for three weeks then a week off the medicine to complete a four-week cycle. Number of cycles given will depend on your subtype and disease status of lymphoma.

Romidepsin may have the following side effects:

• Diarrhoea• Infections• Low blood counts• Nausea• Tiredness

Romidepsin is approved by the TGA and currently awaiting approval to be listed on the PBS however access to Romidepsin can be found in clinical trials around Australia and by access programs through the pharmaceutical company.

Order our lymphoma resource pack

Lymphoma Australia has developed a wide range of useful patient information, covering all aspects of lymphoma. Our resources are designed to increase your understanding of lymphoma and to support patients and their families through the various phases of their lymphoma journey.Order